stockrowInflaRx N.V.
IFRXInflaRx N.V.’s revenue for fiscal 2025 (year ended December 2025) was $33,200.00, down 81.5% from fiscal 2024.
- Revenue
- −128.9%
- EPS
- +90.9%
- Free cash flow
- +59.8%
Quarter to September 2026, against a year earlier
Follow IFRX
Alert me
InflaRx N.V. (IFRX) EV/Sales
As of 6 November 2026, InflaRx N.V. (IFRX) trades at a EV/Sales of 1,845×. Over the past ten years it has ranged from −162× (May 2025) to 4,846× (May 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 411× | (10.96%) |
| FY2024 | 462× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 411× | 172.54% |
| Sep 2025 | 151× | — |
| Jun 2025 | −41.2× | — |
| Dec 2024 | 462× | 221.81% |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| RNAC Cartesian Therapeutics, Inc. compare | 77.4× |
| SLGL Sol-Gel Technologies Ltd. compare | 121× |
| PALI Palisade Bio, Inc. compare | 151× |
| IKT Inhibikase Therapeutics, Inc. compare | 395× |
| IFRX InflaRx N.V. | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)